Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

被引：0

作者：

T. Shiroiwa

T. Fukuda

K. Shimozuma

M. Mouri

Y. Hagiwara

H. Doihara

H. Akabane

M. Kashiwaba

T. Watanabe

Y. Ohashi

H. Mukai

机构：

[1] National Institute of Public Health,Department of Health and Welfare Services

[2] Ritsumeikan University,Department of Biomedical Sciences, College of Life Sciences

[3] Kanagawa Academy of Science and Technology (KAST),Department of Biostatistics, School of Public Health

[4] The University of Tokyo,Breast and Endocrine Surgery Department

[5] Okayama University Hospital,Department of Surgery

[6] Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital,Department of Surgery

[7] Iwate Medical University,Department of Breast Surgery

[8] Sendai Medical Center,Department of Integrated Science and Engineering

[9] Chuo University,Division of Breast and Medical Oncology

[10] National Cancer Center Hospital East,undefined

来源：

Quality of Life Research | 2017年 / 26卷

关键词：

Breast cancer; EQ-5D; Health-related quality of life; Randomized controlled trial; S-1; Taxane;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：445 / 453

页数：8

共 47 条

[31] S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
Yamada, Y.
Denda, T.
Gamoh, M.
Iwanaga, I.
Yuki, S.
Shimodaira, H.
Nakamura, M.
Yamaguchi, T.
Ohori, H.
Kobayashi, K.
Tsuda, M.
Kobayashi, Y.
Miyamoto, Y.
Kotake, M.
Shimada, K.
Sato, A.
Morita, S.
Takahashi, S.
Komatsu, Y.
Ishioka, C.
ANNALS OF ONCOLOGY, 2018, 29 (03) : 624 - 631
[32] Randomized, open-label, phase III, multicenter trial comparing AT (doxorubicin, paclitaxel) versus FAC (5-fluorouracil, doxorubicin, cyclophosphamide) as first-line treatment for patients with metastatic breast cancer
Tjulandin, SA
SEMINARS IN ONCOLOGY, 1999, 26 (06) : 10 - 10
[33] Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer
Yanagimoto, Hiroaki
Okusaka, Takuji
Ishii, Hiroshi
Furuse, Junji
Ohkawa, Shinichi
Fukutomi, Akira
Ioka, Tatsuya
Sho, Masayuki
Nakamori, Shoji
Kitano, Masayuki
Sugimori, Kazuya
Maguchi, Hiroyuki
Imaoka, Hiroshi
Baba, Hideo
Shimizu, Atsushi
Yokota, Isao
Ohashi, Yasuo
Yamaue, Hiroki
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[34] Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses
Ajani, J. A.
Rodriquez, W.
Bodoky, G.
Moiseyenko, V.
Lichinitser, M.
Gorbunova, V.
Vynnychenko, I.
Garin, A.
Lang, I.
Falcon, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[35] Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial
Sadahiro, Sotaro
Suzuki, Toshiyuki
Okada, Kazutake
Saito, Gota
Miyakita, Hiroshi
Ogimi, Takashi
Chan, Lin Fung
Kamei, Yutaro
ONCOLOGY, 2020, 98 (09) : 637 - 642
[36] 5-FU/I-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial)
Sawaki, A.
Yamaguchi, K.
Nabeya, Y.
Sakai, Y.
Osanai, H.
Denda, T.
Furue, H.
Kurihara, M.
EJC SUPPLEMENTS, 2009, 7 (02): : 364 - 364
[37] Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
Nakamura, M.
Takashima, A.
Denda, T.
Gamoh, M.
Iwanaga, I.
Komatsu, Y.
Takahashi, M.
Ohori, H.
Sekikawa, T.
Tsuda, M.
Kobayashi, Y.
Miyamoto, Y.
Kotake, M.
Ishioka, C.
Shimada, K.
Sato, A.
Yuki, S.
Morita, S.
Takahashi, S.
Yamaguchi, T.
ANNALS OF ONCOLOGY, 2018, 29
[38] Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
Komatsu, Y.
Takashima, A.
Denda, T.
Gamoh, M.
Iwanaga, I.
Shimodaira, H.
Nakamura, M.
Yamaguchi, T.
Takahashi, H.
Kobayashi, K.
Tsuda, M.
Kobayashi, Y.
Baba, H.
Kotake, M.
Ishioka, C.
Sato, A.
Yuki, S.
Morita, S.
Takahashi, S.
Shimada, K.
ANNALS OF ONCOLOGY, 2017, 28
[39] Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study
Sho, Masayuki
Shimizu, Atsushi
Yanagimoto, Hiroaki
Nakamori, Shoji
Okusaka, Takuji
Ishii, Hiroshi
Kitano, Masayuki
Sugimori, Kazuya
Maguchi, Hiroyuki
Ohkawa, Shinichi
Imaoka, Hiroshi
Hashimoto, Daisuke
Ueda, Kazuki
Nebiki, Hiroko
Nagakawa, Tatsuya
Isayama, Hiroyuki
Hagiwara, Yasuhiro
Ohashi, Yasuo
Shirasaka, Tetsuhiko
Yamaue, Hiroki
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC)
Yuki, Satoshi
Gamoh, Makio
Denda, Tadamichi
Takashima, Atsuo
Takahashi, Shin
Nakamura, Masato
Ohori, Hisatsugu
Yamaguchi, Tatsuro
Kobayashi, Yoshimitsu
Baba, Hideo
Kotake, Masanori
Amagai, Kenji
Kondo, Hitoshi
Shimada, Ken
Sato, Atsushi
Ishioka, Chikashi
Komine, Keigo
Ouchi, Kota
Morita, Satoshi
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →